Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-PRISM: Cilta-cel in High-Risk Smoldering Myeloma
NCT05767359Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ciltacabtagene autoleucel in smoldering multiple myeloma (SMM), sponsored by Dana-Farber Cancer Institute. Started Apr 2023; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT05767359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05767359.